Background: Notch is a signaling molecule which plays a role in angiogenesis and γ-secretase is required for processing of Notch. In this study, we investigated the effect of γ-secretase inhibitor (DAPT) on tumor angiogenesis in diet-induced obese mice. Methods: 18 mice were divided into three groups; control, obese (diet-induced) and obese+DAPT. After 15 weeks, the obese mice were subjected for tumor induction of CT26 colon adenocarcinoma cells (5 x 10 5 cells). When the tumor size reached approximately 350 ± 50 mm 3 , half of the obese animals received DAPT (10mg/kg/day) subcutaneously. Blood samples were taken after 14 days and the tumors harvested for immunohistochemical staining and capillary density were reported as CD31 positive cells/mm 2 . Results: The obese animals had higher serum leptin and NO concentrations, while, serum VEGF and VEGFR-1 concentrations were not different compare to control group. Administration of DAPT in obese mice signifi cantly reduced serum VEGFR-1 and leptin concentrations and increased serum NO level (p < 0.05). Capillary density in the tumors of obese animals was not different compare to control groups. DAPT administration could not alter capillary density in the tumors. Conclusion: Administration of DAPT in obese mice altered serum angiogenic factors, however, it could not modulate tumor angiogenesis in diet-induced obese mice (Fig. 4, Ref. 26 ). Text in PDF www.elis.sk.
Introduction
Notch signaling is involved during angiogenesis in both physiological and pathological conditions (1, 2) . First time, Ellisen et al reported the role of Notch signaling in growth of T-cell acute lymphoblastic leukemia (3) . Tumor suppressive role of Notch has been documented in some studies, while, the role of Notch signaling in promotion of tumor aniogenesis has also been reported (1, 4) ]. γ-secretase cleaves several proteins involved during angiogenesis process including Notch and inhibitors of this enzymes blocks the cleavage of Notch intracellular domain and inhibits Notch signaling. In the mice lacking γ-secretase activity, development of blood vessels is abnormal and they are at risk of cerebral hemorrhage (5) . Therefore, it is suggested that γ-secretase inhibitors could modulate tumor angiogenesis.
Angiogenesis, the growth of new capillaries from preexisting ones, is a regulated process which is modulated by numerous angiogenic and antiangiogenic factors. Vascular endothelial growth factor (VEGF) and their receptors (VEGFR-1 and VEGFR-2) are the known factors which are involved in physiological and pathological angiogenesis (6, 7) . Moreover, nitric oxide (NO) which is synthesized by endothelial NO synthase (eNOS), is the main endothelium-derived relaxing factor, which has angiogenic properties (8) .
Since obesity is associated with increases risk of cancer including colorectal carcinoma (9) , in the present study, we used a functional γ-secretase inhibitor, DAPT (N-[N-(3,5-Difl urophenaacetyl-L-alanyl)]-S-phenylglycinet-Butyl Ester) (10, 11) to determine the role of DAPT on colon adenocarcinoma cell angiogenesis in diet-induced obese mice.
Materials and methods

Animals
Male Balb/C mice, 5 weeks of age, were used in this study. The mice were purchased from the Pasteur Institute of Iran. The animals were maintained in animal room, 2-3 mice per cage, at 20-25 °C room temperature with 12h light/dark cycle. To induce diet-induced obese mice, 12 mice were fed with high-fat diet (HFD) containing 59 % fat, 27 % carbohydrate, 14 % protein (laboratories BioServ, Cat #F3282, USA). To verify the effect of HFD on induction of dietinduced obesity, we also used a control group (n=6) who received standard diet (Pasteur Institute of Iran). The experimental procedures were in accordance with the guideline of the animal care and ethical committee at the Isfahan University of Medical Sciences.
Induction of tumor
After 15 weeks, the obese mice were subjected for tumor induction by dorsal subcutaneous inoculation of CT26 colon adenocarcinoma cells (5 x 10 5 cells in 500 μl of phosphate buffered saline using 21 gauge needle) (REF). The animals were monitored every day and when the tumor size reached approximately 350 ± 50 mm 3 , the obese animals were randomly divided into two groups: obese and obese +DAPT. The DAPT was dissolved in DMSO (dimethyl sulfoxide) and injected 10 mg/kg/day, subcutaneously (10) . The obese group received DMSO solution with the same volume. Blood samples were taken after 14 days and serums were separated and stored at -70 °C for further analysis. Then, the animals were sacrifi ced and the tumors were harvested.
Immunohistochemistry
The tumors were fi xed in 10 % formalin solution. After paraffi n embedding, the tissues were cut into 5-μm sections, deparafi nized and rehydrated. The sections were stained with standard immunohistochemical protocol with a monoclonal rat anti-mouse CD31 antibody (Abcam Co.). Five sections were selected and CD31 positive cells were counted. Visual count was performed at 40 x magnifi cation in 20 fi elds of each section using an Olympus microscope and angiogenesis was reported as the number of CD31 positive cells per mm 2 .
Serum angiogenic factor measurements
Serum VEGF and VEGFR-1 were measured using enzymelinked immunosorbent assays (R&D systems, Mineapolis, USA). Serum nitrite, the main metabolite of NO, was measured by Griess reagent method (Promega Corp, USA). Serum leptin levels were measured using specifi c sandwich enzyme immunoassay kit (In- vitrogen, Camarillo, CA 93012) and measured according to the manufacturer's instructions.
Statistical analysis
The results are shown as the mean ± SE. Statistical analysis of the data was performed using the One-Way ANOVA. p ˂ 0.05 was considered statistically signifi cant.
Results
Body weight
As we expected, the obese mice presented body weights significantly higher than control group. Administration of DAPT could not signifi cantly change body weight in the obese mice (Fig. 1) . Figure 2 illustrates the changes of serum leptin, NO, VEGF and VEGFR-1 concentrations in experimental groups. The obese animals had higher serum leptin and NO concentrations, while, the serum VEGF and VEGFR-1 concentrations were not different compared to control group. Administration of DAPT signifi cantly reduced serum VEGFR-1 and leptin concentrations in obese mice and increased serum NO level with no signifi cant alteration in serum VEGF level.
Serum measurements
Capillary density in the tumor: effect of DAPT
Capillary density expressed as CD31 positive cells/mm 2 in the tumors of obese animals was not different compared to control groups. DAPT administration could not signifi cantly alter capillary density in the tumors (Fig. 3) . Samples of immunohistochemical staining are shown in Figure 4 .
Discussion
In the present study, obese animals had higher serum leptin and NO concentrations compared to control mice. Leptin is a protein with 16kDa which is secreted predominantly by adipocyte cells. Plasma level of leptin is proportional to adipose tissue mass and several studies reported this correlation. Higher NO in obese animals has been reported in previous studies. It is demonstrated that adipose tissue surrounding blood vessels is a source of NO overproduction in obese mice (12) . Another study reported that HFD signifi cantly increased hypothalamic NO production due to increased nNOS expression which may involve in insensitivity to leptin (13) . NO is not only considered an anti-atherosclerotic factor (14) , but is also involved in angiogenesis process (8) .
In the present study, HFD increased serum nitrite level as a marker of NO production compared to control group. Besides the role of NO in food intake (15), it is involved in angiogenesis process, and has various antiatherosclerotic actions via inhibition of leukocyte adhesion and prevention of smooth muscle proliferation and protection. Abnormalities in the NO cyclic GMP pathway located at the subendothelial space could be involved in impaired vascular response and endothelial dysfunction in diabetic subjects (16) . Benkhoff et al showed that HFD increased cerebral nNOS expression and cerebral and plasma nitrite levels in humans and mice (17) .
After DAPT treatment for 14 days in obese mice, serum VEG-FR-1 and leptin were decreased and serum NO increased compare to obese group not receiving DAPT. However, serum VEGF displayed no signifi cant changes between DAPT-treated and untreated groups. VEGF is the known angiogenic factor which has a key role in physiological and pathological angiogenesis (6) . VEGF has two receptors: VEGFR-1 and VEGFR-2 (18) . VEGFR-1 is a potent negative regulator of VEGFR2 action (7). VEGFR1 is a negative regulator of angiogenesis, While, VEGFR2 has proangiogenic effect and stimulates endothelial cell proliferation and angiogenesis (19) . In tumor tissue, VEGFR1 is the dominant receptor to VEGFR2 (20) . Nitric oxide (NO) is the main endothelium-relaxing factor which is an angiogenic factor (8). Leptin is not only involved in food intake and energy balance, but also, it has angiogenic and mitogenic effects, and possess direct proangiogenic activity (21, 22) . Therefore, it is possible that reduced serum VEGFR-1 and leptin and increased serum NO levels after DAPT treatment alters tumor angiogenesis in obese mice. In agreement with our results, a study in xenograft mouse model indicated that DAPT down-regulated VEGFR1 and up-regulated VEGFR2 (23) . Interestingly, they found that there was no signifi cant change in VEGF level between DAPT and DMSO groups. γ-secretase processes several proteins which play a role during angiogenesis including Notch, CD44 or cadherin (1) a nd we expected that DAPT, a γ-secretase inhibitor, disrupts angiogenesis in tumor. Although studies indicated that γ-secretase inhibitors suppress tumor growth (23) and are involved in postnatal angiogenesis (24), however, in agreement with our results, recently, Zou Y et al reported that DAPT alone (without VEGF) had a little effec t on cell proliferation and they concluded that although DAPT up-regulates VEGFR2 and down-regulates VEGFR1, however, it was not suffi cient to affect endothelial cell proliferation (23) . They also found that in an in vivo tumor model, DAPT disrupt functional vascular remodeling despite increasing the vessel number. In another study, DAPT failed to induce angiogenesis in a wound healing model (25). It is demonstrated that DAPT and DAPM (another γ-secretase inhibitor) dose-dependently inhibited angiogenesis, proliferation and differentiation of tumor endothelial cells (25). Furthermore, in hindlimb ischemia model, DAPT with VEGF promoted angiogenesis, however, intramuscular or intraperitoneal administration of DAPT alone, did not have the same level of improvement (26). Thus, it seems that the effect of DAPT on angiogenesis is dependent on the dose, model of angiogenesis and its administration with or without growth factors.
In conclusion, although administration of DAPT in obese mice with colon adenocarcinoma altered serum angiogenic factors, however, it could not change tumor angiogenesis. More studies need to clarify the exact role of γ-secretase inhibitors on angiogenesis process.
